OC
BNTX icon

Oppenheimer & Co’s BioNTech BNTX Stock Holding History

Oppenheimer & Co’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,678
Closed -$388K – 1445
2023
Q4 		$388K Sell
3,678
-3,078
-46% -$310K 0.01% 1049
2023
Q3 		$734K Sell
6,756
-2,021
-23% -$224K 0.02% 787
2023
Q2 		$947K Sell
8,777
-1,535
-15% -$173K 0.02% 718
2023
Q1 		$1.28M Sell
10,312
-6,155
-37% -$845K 0.03% 595
2022
Q4 		$2.47M Buy
16,467
+3,877
+31% +$597K 0.06% 386
2022
Q3 		$1.7M Buy
12,590
+137
+1% +$20.9K 0.04% 482
2022
Q2 		$1.86M Sell
12,453
-772
-6% -$118K 0.04% 485
2022
Q1 		$2.26M Sell
13,225
-3,267
-20% -$549K 0.04% 470
2021
Q4 		$4.25M Buy
16,492
+26
+0.2% +$7.12K 0.07% 302
2021
Q3 		$4.5M Sell
16,466
-1,709
-9% -$543K 0.08% 279
2021
Q2 		$4.07M Buy
18,175
+5,168
+40% +$975K 0.07% 316
2021
Q1 		$1.42M Buy
+13,007
New +$1.38M 0.03% 577

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Oppenheimer & Co's BNTX Position: Q1 2024 in Review

Oppenheimer & Co sold out of BioNTech (BNTX) in Q1 2024, closing a stake of 3,678 shares — an estimated $388K sold.

Oppenheimer & Co first reported a position in BNTX in Q1 2021 and held it in 12 quarters. The position peaked at $4.5M in Q3 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2024.

  • Oppenheimer & Co reported no remaining BioNTech position as of Q1 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 3,678 BioNTech shares in Q1 2024, an estimated $388K.
  • Oppenheimer & Co first reported a position in BioNTech in Q1 2021 and held it in 12 quarters.
  • Oppenheimer & Co's BioNTech position peaked at $4.5M in Q3 2021.
  • 287 funds tracked by Wall St. Rank held BioNTech as of Q1 2024.

Based on Oppenheimer & Co's 13F filing for Q1 2024, filed 7 May 2024.